Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You might be on to something. There may be something to be learned from testing these people's pkc levels. You ought to pass it along to NeuroDiagnostics.
Yeah. The brain is amazing. What about those people that can remember everything in detail about any day in the past you call out to them.
Snake oil might be good for something out there. I guess Merck wants to cover all bases.
So, you expect it will get to $10 before it dumps? What price did you get in at?
When you think about it, we all are in this pump and dump. I'm dumping my shares at $200 per share.
Come on rayovacAAA, you just gave me a bullish case for the chances of success of the trial. I am looking for bearish points of views stating why the trial should fail. I am seriously looking for this to make sure I’m not missing something.
I'm still waiting on rayovacAAA to comment on the results of the patients in the 20ug arm and not on memantine in the previous trial.
rayovacAAA, can you explain any negative comments you have on the results from the patients not on memantine in the previous trial?
I'm thinking after the drug has cleared the body, would the receptors be sensitized in any way, having a positive or negative effect to the trial. The reason I hope the washout patients were limited in this trial is because of this unknown possibility.
The only change in this confirmatory trial from the previous trial that I can see is the washout period. I wish I knew more about the washout procedure other than it being at least 30 days. I know that it takes about 2 weeks for memantine to clear the body. Wondering if there are any residual affects on the neuronal receptors, positive or negative, after the memantine has cleared the body. I hope the company limited the number of memantine washout patients as much as possible. I'm just trying to think of possible negative scenarios to tone down my enthusiasm, that's all.
Trials are all about “IF”s. But I can tell you that NTRP's “IF” has at least a five time higher chance of success than AVXL's “IF”. IMHO
I agree, thanks runncoach. If this trial doesn’t succeed, it won’t be your fault. But boy, if this thing goes as I suspect it will, let me know your favorite charity. :)
As I read the article runncoach just posted, I could not help but break out into song— “ We're in the moneyyyy, we're in the moneyyy.......” Lol
I haven’t seen any impressive results from any of the trials on this list that I’ve looked that. With all this interest in AD - if we have impressive results, we will be bought-out so fast it will make your head spin.
Check out this interesting site. Boy, there's a lot of interest in AD. It's from July 2017.
https://www.usagainstalzheimers.org/sites/default/files/2018-01/alzheimers-drugs-development-pipeline-2017.pdf
I'm sorry I guess I missed it. Why do you think NTRP is a pump and dump?
You mean the way Wall Street was impressed with Biogen's claims a couple of weeks ago?
I just listened to the interview again. Dr. Alkon really laid it out there. You have to listen to it more than once to truly take it all in. It made me look for more money to buy more shares. We have a tiger by the tail here.
I may be in the minority here, but I think Dr. Alkon could have done better in the interview. He knows the science and the drug so well, and did a very good job at laying out all the facts and the background research. But I think he could have done a better job at pointing out how memantine negatively affected the trial results. Did he discuss how memantine counteracts the mechanism of action of Bryostatin? He may have but it what buried in other facts. He should come out early and explain this.
I lot of this may be flippers, but the churn is needed.
I just called IR and left a message suggesting, now would be a good time to crank up the PR in light of BP discontinuing their trials. The call may not help, but it couldn’t hurt.
Did you suggest they should PR?
This will be a good time for the company to put out a PR.
Yeah, I can't wait til I’m saying “What knuckle heads are selling at $15 before results?”. Lol
The question is - who is selling at these low prices?
Three steps forward and two steps back. I'll take it.
I understand. They would've been able to get apples to apples comparison. The first 15 weeks would have been exactly the same as the previous trial, the extended weeks of evaluation would not be primary endpoints and no drug would have been introduced.
A little hindsite thinking. If the company had thought out of the box a little in designing this current trial, they should have extended it to week 17 or even week 19, using these weeks only to evaluate the patients. Keeping everything else the same. This would have been good just in case the treatment needed a little more time to produce that increase in cognition we saw between week 13-15. Week 11would still be the last dose. If the results began to turn down during this extended period it would not negatively affect the trial expectations, it would have been expected at that point.
I'm not shakened.
I agree there is a risk of failure, but disagree with “high” risk. Can you put a percent on it?
If this trial confirms the previous, BP wouldn’t need us to build out the platform. They will do it themselves. They will also have a fear that their competitors will gobble us up. The share price will be dictated by BP by what they are willing to pay.
I've been sitting here trying to think of—with similar results to previous non-memantine arm, what would prevent the stock price from reaching $50 per share ($1.25 billion m/c). I can't think of any.
Never thought I would say bring on the tsunami. Lol
I'm looking at the price run up before the last trial. It started in January. Was that due to the introduction of the stock to the NASDAQ or in anticipation of the results release in April? I think the spike up to $29 in March could have been manipulated in order to short back down to under $20.
If results are positive to the level of the previous trial, what likelihood would you give that BP will skip partnership and go for a BO.
I want to not look at the stock price for about a week. But when I come on this site - there it is :(
Couldn’t the company buy back about a million shares to support the stock and sell it back when the volume and price is higher closer to read out? Why not since they have not announced any immediate use for the money.
WOW!! I never knew that was the reason for shortening the trial. It's almost too bizarre to be true. That would have been really sad if a drug that could potentially reverse Alzheimer’s was never developed because of something as stupid as that.
Ok that may be were my logic is off. So, they already had the results when they decided to not extend the trial?
I agree learn and move on. But the pessimist side of me think about the amount of money the company raised in a not favorable deal, did they see anything in the trial that sparked them to go for that much money. I know the trial is supposed to be blinded, but last time they new something. By not knowing their plans for the money allow my mind to wonder.